about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

With all eyes on Chi­nese-on­ly on­col­o­gy da­ta, Co­herus and Jun­shi un­cork win for PD-1 drug in esophageal can­cer

4 years ago
R&D
China

FDA push­es back a re­view date for TG's 'U2' com­bo as the biotech steels it­self for up­com­ing ad­comm

4 years ago
FDA+

Long­time Hutchmed CEO Hogg de­parts, hand­ing over the reins amid US ex­pan­sion plans

4 years ago
People

A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

4 years ago
Financing
Startups

A new JAK in­hibitor earns FDA nod in myelofi­bro­sis, set­ting up a fight with In­cyte, Bris­tol My­ers

4 years ago
FDA+

Blue­print part­ners up with a de­grad­er-fo­cused 'van­t' as part of pipeline-boost­ing cam­paign

4 years ago
Deals

Japan, UK pledge new funds to CEPI's $3.5B pan­dem­ic pre­pared­ness plan, with eye to­ward fu­ture out­breaks

4 years ago
Coronavirus

Ab­b­Vie cuts away part of its part­ner­ship with Mor­phic on in­te­grin re­search for fi­bro­sis

4 years ago
R&D

Kiniksa inks li­cens­ing deal to take a Re­gen­eron castoff in­to Asian mar­kets

4 years ago
Deals

Lil­ly breaks the bank on the po­ten­tial for RNA with $700M in­vest­ment in Boston's Sea­port

4 years ago
R&D
Cell/Gene Tx

Bay­er's next-gen drug Nube­qa aces sur­vival test in metasta­t­ic prostate can­cer, putting it in com­pe­ti­tion with gi­ants

4 years ago
R&D

Yu­man­i­ty's ug­ly demise con­tin­ues with plans to axe 60% of staff in search for 's­trate­gic al­ter­na­tives'

4 years ago
People

Ava­lo Ther­a­peu­tics shuf­fles lead­er­ship team as the flail­ing biotech search­es for a port in the storm

4 years ago
People
Coronavirus

J&J jumps on the RNA band­wag­on, ink­ing dis­cov­ery deal with Remix for a po­ten­tial­ly new class of drugs

4 years ago
Deals

In an un­usu­al piv­ot, Swiss biotech Basilea looks to ditch can­cer pipeline in fa­vor of — an­ti-in­fec­tives?

4 years ago
R&D

With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

4 years ago
R&D

A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

4 years ago
Financing
Startups

FDA keeps clin­i­cal hold in place on Lari­mar's lead drug with job cuts like­ly on the hori­zon

4 years ago
FDA+

De­nali of­fers more clues on clin­i­cal hold, turn­ing over FDA wor­ries on pre­clin­i­cal tox for Alzheimer's drug

4 years ago
FDA+

Af­ter Lil­ly's sin­til­imab shel­lack­ing, Chi­na-on­ly on­col­o­gy tri­als are fac­ing a new — and un­fa­vor­able — re­al­i­ty at ...

4 years ago
R&D
China

Cell ther­a­py pi­o­neer Mark Frohlich takes the helm at tiny In­dap­ta as a suite of big-name back­ers jump aboard

4 years ago
People
Financing

At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the ...

4 years ago
R&D

Ed­i­to­r­i­al: Did Rick Paz­dur's big 'no' on Lil­ly's Chi­na-born PD-1 al­so spell the end for price dis­rup­tion?

4 years ago
FDA+

Two Pan­dion vets jump back in­to the start­up world, this time us­ing ma­chine learn­ing to build bet­ter im­munol­o­gy drugs

4 years ago
Startups
Discovery
1234 Next page Last page
A service from the Financial Times